Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8119446 | 0.89 | KMT2A (0.65) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL27686848 | 0.83 | KMT2A (0.49) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL11463026 | 0.83 | KMT2A (0.63) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL8628969 | 0.82 | KMT2A (0.61) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL20505093 | 0.82 | KMT2A (0.61) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL10630642 | 0.82 | KMT2A (0.61) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL4331526 | 0.82 | KMT2A (1.00) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL834652 | 0.82 | RAB9A (0.50) | KMT2AMEN1CYP1A2LMNA | |
| SCHEMBL7759208 | 0.82 | KMT2A (0.47) | KMT2AMEN1CYP1A2ALDH1A1HPGD | |
| SCHEMBL28272304 | 0.80 | KMT2A (0.59) | KMT2AMEN1CYP1A2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8165289-A | — | — | None | — | — | JP | disclosed |
| CN-115515958-B | Novel sulfonamide (Menin-MLL) interaction inhibitor, preparation method and medical application thereof | 成都苑东生物制药股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116693533-A | Five-membered heteroaromatic ring type gin-MLL interaction inhibitor, preparation method and medical application thereof | 成都硕德药业有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| WO-2023011446-A1 | NOVEL SULFONAMIDE MENIN-MLL INTERACTION INHIBITOR, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023011446-A1 | NOVEL SULFONAMIDE MENIN-MLL INTERACTION INHIBITOR, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 成都苑东生物制药股份有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-111356695-B | Novel tricyclic compounds | 北京加科思新药研发有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115515958-A | Novel sulfonamide menin-MLL interaction inhibitor, and preparation method and medical application thereof | 成都苑东生物制药股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220363673-A1 | 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases | PFIZER INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3990452-A1 | 5-(THIOPHEN-2-YL)-1H-TETRAZOLE DERIVATIVES AS BCKDK INHIBITORS USEFUL FOR TREATING VARIOUS DISEASES | Pfizer Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-1434775-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-07-01 | — | — | US | disclosed |
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-02-19 | — | — | US | disclosed |
| WO-2003057676-A1 | 3,4-DI-SUBSTITUTED PYRIDAZINEDIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003031440-A1 | 3,4-DI-SUBSTITUTED MALEIMIDE COMPOUNDS AS CXC-CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1208091-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001017982-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2001-03-15 | — | — | WO | disclosed |
| JP-H08165289-A | PRODUCTION OF THIENYL ETHER DERIVATIVE | TOKUYAMA CORP | 1996-06-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KMT2A 1790/4885MEN1 4151/4885CYP1A2 116/4885 |
| US-20220363673-A1 | 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases | BCKDK, PDK4, PFKL | KMT2A 2827/4885MEN1 4725/4885CYP1A2 1196/4885 |
| US-20040127521-A1 | 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP3, CASP2 | KMT2A 4450/4885MEN1 2053/4885CYP1A2 384/4885 |
| US-20040034229-A1 | 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists | CXCR1, CCR1, CCL2 | KMT2A 4497/4885MEN1 861/4885CYP1A2 3329/4885 |
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | CXCR1, CCR1, ACKR3 | KMT2A 4671/4885MEN1 3342/4885CYP1A2 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.